CD274 and hepatocellular carcinoma: In HCC patients treated with anti–PD-1/PD-L1 monotherapy, objective response rates (ORRs) ranged from 8 to 20%, and disease control rates (DCRs) ranged from 33 to 73%, except one was 10% (Table 1).